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Abstract
Of all the known cancers, oral cancer is the most preventable and it is the second most 
deadly cancer after the breast cancer. Out of 609,640 deaths of overall cancers, 13,500 died 
of oral cancer. In spite of this enormous increase in loss of life, there are no useful drugs 
to treat oral cancer. Sequencing human genome identifies with precision and accuracy the 
specific mutations responsible for causing oral cancer. In this chapter, a novel approach 
to design drugs to attack mutated genes in squamous cell carcinoma responsible for caus-
ing oral cancer is proposed. Alkylating aziridines attack single-stranded DNA shutting 
off genes. Using dinitrobenzamide dye as a carrier for aziridine, we successfully made a 
novel class of drugs (CB 1954) which shuts off gene of a solid tumor, Walker Carcinoma 
256, in rats. We translated the animal work in humans by using quinone as a carrier for 
aziridines making AZQ (US Patent 4,146,622) for attacking glioblastoma for treating brain 
cancer in humans. We propose to search for a carrier for aziridines to attack squamous cell 
carcinomas to treat oral cancer. Ethical issues are discussed. Since tobacco smoking causes 
oral cancer, it is the most preventable disease.
Keywords: nicotine, nicotine N-oxide, aziridines, quinone, squamous cells carcinoma, 
glioblastoma, melphalan, pharyngeal carcinoma, nitrogen mustard, adeno-carcinoma, 
nitro-benzamide, nucleotide, codon, oncogene, carbamate, mitochondrial cells, AZQ
1. Historical background
Use of tobacco products will kill you. It does not matter either you smoke tobacco or you use 
a smokeless tobacco or nicotine patch or smoke e-cigarettes. Last year, 13,500 smokers died 
of oral cancer. Out of 450,000 new cancer cases diagnosed this year, 37,000 new cases will be 
diagnosed for 13 different types of oral cancer which include cancer of the lips, salivary glands, 
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buccal cavity, pharynges, oropharyngeal, laryngeal, nasopharyngeal, hypopharyngeal, etc., 
and respiratory tract and finally lung cancers. It was Professor Ross of London University 
who developed oral cancer drug called melphalan (phenylalanine moiety is the carrier for the 
nitrogen mustard) to treat pharyngeal carcinoma [1]. Melphalan cross-links both strands of 
DNA shutting off genes. Statistics is worst for smokers. Over 155,700 Americans died of lung 
cancer last year and over 222,500 will be diagnosed this year. Compare the US mortality, the 
worldwide figure is ten times as high. While squamous cell carcinoma is responsible for caus-
ing oral cancer, adenocarcinoma is one of the deadliest forms of lung cancers. Most patients 
die within 5 years of their diagnosis. Tobacco smoking kills faster.
For years, we have been trying to answer three important questions: What is cancer? What 
causes cancer? And how could we diagnosed treat and prevent cancer. For this chapter, I 
have divided my presentation in three parts. First, I will provide some historical background; 
second, I will describe how efforts are being made to develop novel drugs to treat cancer; and 
finally, I will share some ethical problems we are facing today.
Today, we must tell all smokers in the world that tobacco smoking whether it is the regular 
cigarette or e-cigarette or nicotine patch or the use of smokeless tobacco, and all tobacco mod-
ifications contains nicotine, and it is the nicotine which causes oral and lung cancers. If you 
are diagnosed with lung cancer, you are most likely to die within 5 years. Tobacco companies 
have known this fact for more than half a century. In the late 1930s, German scientists dis-
covered the fact that tobacco tar causes lung cancer [2]. When Adolf Hitler was elected as the 
Chancellor of Germany, he authorized 100,000 Deutsch Marks to a science research institute 
in Munich to isolate and identify all components of tobacco tar which causes lung cancer. He 
ordered all his uniform officers including pregnant women not to smoke tobacco. These facts 
are still available in the National archive. Tobacco companies are aware of these facts. For 
the past 60 years, tobacco companies have lied to us. No one was spending more money on 
tobacco research than tobacco companies themselves and yet when they confirmed German’s 
finding in early 1960s that smoking causes lung cancer, they hid the fact from general public. 
For almost 50 years, the greedy tobacco companies exposed millions of smokers around the 
world with thousands of deadly chemicals with disastrous consequences. Up to this time, 
more than 6000 toxic chemicals have been isolated and identified from tobacco tar and 60 of 
those chemicals are deadly and known to cause cancer. The main constituent of tobacco tar 
nicotine is one of the most addictive chemicals isolated and is probably more addictive than 
opium. In India, the second most populous nation on Earth, last year, of the 1 million people 
who died of cancer, almost a quarter million died of lung cancer. Last year alone, about 3 mil-
lion people died of lung cancer around the world. By the year 2020, smoking will most likely 
kill about 10 million people worldwide. Most smokers will prematurely die in their middle 
ages, cutting 20–25 years from their life expectancy. If we examine the death rate during the 
last 48 years, from 1950 to 1998, you will be shocked to learn that about 50 million men and 
10 million women died of cancers by tobacco smoking and related illnesses.
The tobacco companies have flooded so much money in the Congressional and Senatorial 
election campaign, in the US alone, the US senate had voted not to ban tobacco sale to school-
aged teenagers. Greedy tobacco executives won the day and needy millions around the world 
lost the day. Now, tobacco companies will be exporting over 150 billion cigarettes per year to 
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the Asian continent particularly targeting India and China where almost half of the world’s 
population live. It is a sad day for all of us. The young people, who are getting addicted to 
smoking today, will start dying 20 years from now. Of all cancers, tobacco smoking remains 
the single major preventable cause of cancer deaths in the world.
2. What is cancer?
Cancer is a very ancient disease. The early Greek coined the term cancer. They thought that 
this unusual disease spread like a crab so they were the first to call it a cancer or crab. The 
answer to the first question is that cancer is the abnormal growth of the normal cells due to 
accumulation of mutations over lifetime.
Our body is made of about 100 trillion cells. These cells are constantly being replaced by simi-
lar young fresh cells. For example, your white blood cells (WBCs) live for about 120 days. They 
are replaced by other white blood cells. Liver cells make more liver cells and replace old liver 
cells with new liver cells; lung cells make new lung cells. When this normal cell regulation 
breaks down, liver cells do not produce liver cells; they produce altered cells called mutant 
cells. Mutation is caused by exposure to radiations, chemical pollutions, viral infection, or 
genetic inheritance. The changed cells grow much faster than the normal cells and they form a 
lump, we call it a tumor. As tumor grows, it spreads over to the nearby blood circulating ves-
sels. When tumor grows over these vessels, it draws more nourishment than the normal cells. 
Some of the tumor cells break off and split and plunge in the blood stream. These live tumor 
cells flow in the blood stream and travel wherever the blood goes. If the blood goes to the 
brain, the free floating tumor cells deposit in the brain and start growing as the brain tumors 
called metastasized cells. Although the cancer may have started in the lungs from smoking, it 
may spread to the brain or to other organs of our body. Only cancer cells spread this way; we 
call these migratory deposits metastasized cells, and only metastasized cells invade neighbor-
ing organs causing spread of cancer. We have no cure against metastasized cancers.
How many kinds of cancers do we have? There is a cancer for every tissue type in our body. 
There are 220 types of tissues in our body. Every tissue type in our body can suffer from 
cancer because every tissue in our body is replaced cells by cells with younger cells; they can 
either be replaced by normal cells in healthy people or they can also be replaced by abnormal 
or mutated cells when we get cancer. Would you believe that even your bones are being 
replaced? You could also get bone cancer.
3. What causes cancer?
Short answer is exposure to radiations, chemical pollutants like smoking, viral infection, or 
genetic inheritance. This is the most important question and I want to spend more time explain-
ing the causes of cancer. This is where we spent most of the $30 billion during the lasts 30 years 
trying to understand how normal cells become abnormal. If we understand how they become 
abnormal, we should be able to treat them.
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In 1971, President Richard Nixon declared war on cancer and released hundreds of millions 
of dollars for cancer research. He challenged Americans, the way President John Kennedy had 
challenged Americans a decade earlier to land men on the moon and bring them back safely. 
Although both presidents had great ideas, but there was a major difference.
At the time President Kennedy made that famous speech in the US congress, most of the 
engineering problems had already been worked out. For example, we already knew the 
engine thrust and its lift off power needed to leave Earth’s gravity. It was calculated to be 
7 miles/minute or burning fuel in the absence of air to excel the spacecraft. These engineering 
problems had already been solved and the knowledge was already available. Only money 
and trained men power were needed to build the spacecrafts. Within 10 years of that speech, 
President Kennedy’s dream was turned to reality. On July 20, 1969, Americans landed men on 
the moon and brought them back safely.
But when President Nixon declared war on cancer, money was made available, but the knowl-
edge was not there. We did not exactly know the inner working of a single living cell and 
how a normal cell functions, and we did not know why the normal cell becomes abnormal 
or cancerous. Some basic knowledge was available. In 1953, the big discovery was made in 
Cambridge University, England. Crick and Watson had determined the double helical struc-
ture of the genetic material DNA and postulated how the living cells divide and cells grow, 
and they were awarded Nobel Prize for their discovery [3]. Armed with this knowledge, we 
were ready to understand how a normal cell functions. Crick and Watson also opened the 
doors for the Nobel Prize Club. Every year, since then, a new Nobel Laureate was added to the 
genetic club. Soon after, Marshall Nirenberg broke the genetic code and unlocked the secret 
of life by showing that only three nucleotides code for an amino acid, the building block of 
protein. The remaining codes were deciphered by Salvador Ochoa, followed by an Indian 
Scientist, Govind Khorana who shared the Nobel Prize with Walter Gilbert.
After President Nixon’s speech, it had taken about 20 years to understand how a normal cell 
functions and how it becomes abnormal by exposure to radiations, chemical pollutants, viral 
infection, or genetic inheritance. Let me summarize below the work of a dozen Nobel Laureates: 
To understand cancer, you have to understand how a normal cell functions and how it becomes 
abnormal. We made step by step progress over the past 30 years. First, you might ask why we 
study a single cell and why a single cell is so important. The fact is our life begins with a single 
cell. You and I are the loving union of our parents. Both parents contribute half the genetic mate-
rial to each cell. Our father contributed one sperm and our mother contributed one egg. When 
the egg and sperm join together, we were conceived. We grow as a single cell in our mother’s 
womb. This single cell has a set of complete instructions to construct us within in 9 months. By 
the time we are grown up to adulthood, that single cell makes over 100 trillion copies of itself.
During replication, if we introduce slight error in the nucleotide sequence called mutation by 
exposing to radiations or chemical pollutants including nicotine, viral infection, or genetic inher-
itance, the error is copied in every other cell. At this stage, pregnant mothers should be extremely 
careful what they eat and what they drink and to avoid exposing the fetus from the secondhand 
smokers and should stay away from smokers as far as they could. Every cell in our body has a 
complete library of our genome and carries complete instructions to make our brain, our nose, 
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our ears, our arms, and our legs. Although each cell carries complete instructions to make all the 
organs, not all cells make all organs, but each cell begins to receive specific instructions to take a 
different role as it begins to make more copies. We call this process the cell differentiation.
3.1. Mutations
Damage to DNA nucleotide called mutations produces disastrous change in the information 
molecules. As I said above, mutations are caused by exposure to radiations, chemical pollu-
tion, viral infection, or genetic inheritance. In addition to hundreds of chemicals isolated from 
tobacco tar, the most potent carcinogen is nicotine N-oxide. As mutation begins in a single 
biological molecule, it is called a point mutation. To study changes in genetic profile of a single 
cell, we examine the entire genome of the same single cell. As cells grow rapidly, other mis-
takes in DNA replications are most likely to occur such as deletion, insertion, or inversions of 
nucleotide sequence. Such additional mutations are responsible for causing major diseases. 
Before the completion of Human Genome Project, NCI screened thousands of chemicals, plant 
extracts, and animal extracts for their antitumor activity. By trial and error, one in several thou-
sand turned out to be useful. There was a need to make a rational approach to design drugs.
In 1990, United State Congress authorized 3 billion dollars to NIH to decipher the entire 
human genome within 15 years that is the total genetic information that makes us human 
called the Human Genome Project. Thousands of scientists from 6 industrialized nations and 
20 biomedical centers joined our effort, and within 13 years, the entire human genome was 
deciphered and published in the scientific journal Nature [4–8] and linked to website. If you 
have an access to a computer keyboard, you have access to all that information.
On April 3, 2003, we read the Human Genome, the entire book of life. We found that less than 
2% of the genome codes for proteins and the rest is the noncoding region which contains 
switches to turn the genes on or off. We can cut and paste genetic letters in the noncoding 
region which could serve as markers and which has no effect, but a slight change in the coding 
region makes a normal cell abnormal or cancerous.
A single cell is so small that we cannot even see with our naked eyes. We have to use a powerful 
microscope to enlarge its internal structure. Under an electron microscope, we can enlarge that 
one cell up to nearly a million times of its original size. Under the electron microscope, a single 
cell looks as big as our house. There is a good metaphor with our house. For example, our house 
has a kitchen, the cell has a nucleus. Imagine for a moment that our kitchen has 23 volumes 
of cookbooks which contain 24,000 recipes to make different dishes for our breakfast, lunch, 
and dinner. The nucleus has 23 pairs of chromosomes which contain 24,000 genes which carry 
instructions to make proteins. Proteins interact to make cells; cells interact to make tissues; and 
tissues interact to make an organ and several organs interact to make a man, a mouse, or a mon-
key. In every cell of our body, we carry 16,000 good genes, 6000 mutated genes responsible for 
6000 diseases, and 2000 pseudogenes that have lost their functions, during evolutionary time.
Our entire book of life is written in four letters, and they are A (adenine), T (thymine), G 
(guanine), and C (cytosine). These four chemicals are called nucleotide and they are found in 
the nucleus of all living cells including humans, plants, and animals. Instruction in a single 
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gene is written in thousands of AT/GC base pairs that are linked together in a straight line and 
we call them DNA (deoxyribonucleic acid—Nobel prize was awarded to Crick and Watson 
for describing the double helical nature of the DNA structure). When thousands to millions 
of AT/GC base pairs contain information to make a single protein, we call that portion of 
AT/GC base pairs a gene (Nobel Prize was awarded to Khorana and Gilbert for making a 
functional gene). The genes begin to function with a start codon (AUG) and stop working at 
the following three stop codon: UGA, UGG, and UAG. After the stop codon, no more amino 
acids are added and DNA synthesis stops. If we count all the AT/GC base pairs in a single cell 
of our body, we will find that there are 3.2 billion pairs present in every cell. The entire AT/
GC sequence of 3.2 billion base pair is called the human genome or the book of our life which 
carries total genetic information to make us.
We deciphered all 46 chromosomes. What surprises us most is that our genome contains 
6,400,000,000 nucleotide bases, half from our father and half from our mother. Less than 2% 
of our genome contains genes which code for proteins. The other 98% of our genome con-
tains switches, promoters, terminators, etc. The 46 chromosomes present in each cell of our 
body are the greatest library of the human book of life on planet Earth. The chromosomes 
carry genes which are written in nucleotides. Before sequencing (determining the number 
and the order of the four nucleotides on a chromosome), it is essential to know how many 
genes are present on each chromosome in our genome. The Human Genome Project has 
identified the following genes on each chromosome. We found that the chromosome (1) is 
the largest chromosome carrying 263 million A, T, G, and C nucleotide bases and has only 
2610 genes. The chromosome (2) contains 255 million nucleotide bases and has only 1748 
genes. The chromosome (3) contains 214 million nucleotide bases and carries 1381 genes. The 
chromosome (4) contains 203 million nucleotide bases and carries 1024 genes. The chromo-
some (5) contains 194 million nucleotide bases and carries 1190 genes. The chromosome (6) 
contains 183 million nucleotide bases and carries 1394 genes. The chromosome (7) contains 
171 million nucleotide bases and carries 1378 genes. The chromosome (8) contains 155 million 
nucleotide bases and carries 927 genes. The chromosome (9) contains 145 million nucleotide 
bases and carries 1076 genes. The chromosome (10) contains 144 million nucleotide bases 
and carries 983 genes. The chromosome (11) contains 144 million nucleotide bases and car-
ries 1692 genes. The chromosome (12) contains 143 million nucleotide bases and carries 1268 
genes. The chromosome (13) contains 114 million nucleotide bases and carries 496 genes. The 
chromosome (14) contains 109 million nucleotide bases and carries 1173 genes. The chromo-
some (15) contains 106 million nucleotide bases and carries 906 genes. The chromosome (16) 
contains 98 million nucleotide bases and carries 1032 genes. The chromosome (17) contains 
92 million nucleotide bases and carries 1394 genes. The chromosome (18) contains 85 million 
nucleotide bases and carries 400 genes. The chromosome (19) contains 67 million nucleotide 
bases and carries 1592 genes. The chromosome (20) contains 72 million nucleotide bases 
and carries 710 genes. The chromosome (21) contains 50 million nucleotide bases and car-
ries 337 genes. Finally, the sex chromosome of all female called the (X) contains 164 million 
nucleotide bases and carries 1141 genes. The male sperm chromosome (Y) contains 59 mil-
lion nucleotide bases and carries 255 genes.
If you add up all genes in the 23 pairs of chromosomes, they come up to 26,808 genes and yet 
we keep on mentioning 24,000 genes. The remaining genes are called the pseudogenes. For 
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example, millions of years ago, humans and dog shared some of the same ancestral genes; 
we both carry the same olfactory genes. Since humans do not use these genes to smell for 
searching food, these genes are broken and they lose their functions in humans, but we still 
carry them. We call them pseudogenes. Recently, some Japanese scientists have activated the 
pseudogenes; this work may create ethical problem in future as more and more pseudogenes 
are activated.
The above DNA nucleotide bases constitute the genetic map of the normal human being; what 
makes them abnormal and makes us sick is the mutation in the coding regions of the genome. 
Now, we can examine the tumor genome of the oral cancer patients to identify specific muta-
tions responsible for causing the disease. As I said above, less than 2% of the genome codes 
for amino acids. Slightest damage to the coding regions of the four nucleotides A, T, G, and C 
either by radiations, chemical pollution (from tobacco tar), genetic inheritance, or viral infec-
tion or by insertion, deletion, or inversion of the nucleotide bases code for wrong or abnormal 
amino acids resulting in diseases.
Although you and I are both human and yet no two individuals look the same because the 
AT/GC base pairs in each of us are arranged slightly differently, a difference of one nucleotide 
in a thousand base pair. The amazing fact is that out of 3,000,000,000 AT/GC base pairs, only 
3 pairs of AT/GC code for a single amino acid, the building blocks of protein, called a codon 
(Nobel Prize was awarded to Nierenberg and Ochoa). Codons are the most important col-
lections of AT/GC base pairs because they have correct instructions to make the right amino 
acids (there are only 20 amino acids; they randomly combine to make a protein). Thousands 
of amino acids make a protein and thousands of proteins make a cell; billions of cells make a 
tissue and hundreds of tissues make an organ and several organs make an individual such as 
you and me. This is how normal cell functions and we begin to grow.
As I said above, the old cells begin to die and they are constantly being replaced by healthy 
cells. Why do the normal cells become abnormal or become cancerous? Any factor that dis-
rupts the 2% of the coding region of our genome will alter its function by slightly altering 
its code; an altered codon will code for a wrong amino acid and a wrong amino acid will 
give a wrong protein and it will make normal cell abnormal. When the functions of codons 
are disrupted intentionally or unintentionally, we alter the codon’s function. For example, 
intentionally we alter a codon by smoking and unintentionally by exposure to environmental 
pollution such as chemicals or radiations. Altered codons have wrong information to make 
wrong amino acids. Wrong amino acids make wrong proteins and wrong proteins make 
wrong cells and wrong cells grow much faster than the normal cells and become abnormal or 
cancerous and they form a lump, we call these lumps tumors.
Four factors will disrupt a codon’s function. Two are minor such as viruses and inherited 
oncogenes, and two are major such as radiations and chemical pollutants in our environment. 
Let me explain how a codon is altered:
3.1.1. Virus
HPV causes more than 32,000 cases of cancer including oral cancer every year in the US. It is 
also very preventable by giving HPV vaccine for children at ages 11–12 which can protect them.
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Viruses are not considered germ in the classical sense because they lack the ability to repro-
duce its progeny independently. To reproduce their own kind, viruses attack DNA of living 
cells, whether they are humans, animals, or plant cells. Viruses are also fragments of DNA 
that have the ability to merge in the host cell DNA and become integrated and invisible. They 
infect (merge) host’s DNA and alter its functional machinery in such a way as to make protein 
and progeny for themselves. Not all viruses are bad. If all viruses kill their host cells, they will 
die too. Only a handful of virulent viruses destroy host cells. For example, AIDS viruses in 
human disrupt the codons and cause a unique cancer in AIDS patients called Kaposi carci-
noma. Hardly anyone survives that cancer.
3.1.2. Oncogene
Oncogenes are also fragments of mutated DNA, but they are always bad. They are complete 
genes that have the instructions to make a specific bad protein. Such genes are called onco-
genes (cancer-causing genes). Our institute's, NIH's, past Director, Dr. Harold Varmus, was 
the first man to identify an oncogene in humans. For his work, Dr. Varmus shared a Nobel 
Prize with Dr. Michael Bishop.
From here begins one of the most exciting stories that explain the causes of cancer. In the 
early 1990s, some scientists in England were studying cancer-causing viruses. When scien-
tists injected cancer-causing viruses to animals, they found that sometimes viruses grow and 
other times they do not. On close examination, they detected a background protein in all 
cells. Whenever the background protein is absent, cancer-causing viruses grow and the animal 
develops cancer. Whenever the background protein is present, cancer-causing viruses will not 
grow. They called it the background Protein 53 or (P53). They identify the gene that makes P53 
protein and they named P53 gene. Since cancer is suppressed in the presence of P53, scientists 
named P53 as cancer suppressor proteins. When a normal cell is damaged, the surround-
ing cells grow to make P53 protein to repair the damage. When healing is complete, the P53 
protein stops the cells from further growth. If there is a mutation in the P53 gene, P53 loses 
its function and the cell growth will not stop and grow continuously and become cancerous.
As I said above, that gene is a collection of codons and each codon is made of three pairs of AT/
GC. Hundreds of thousands to millions of AT/GC base pairs combine to form gene-53. Now, 
we know that the codon in P53 is sensitive to mutation by chemicals, radiations, viruses, and 
oncogenes. If you cause a slight defect in the codon by altering one letter of AT/GC base pair, 
the entire P53 gene becomes defected. Defected P53 cannot produce background protein that 
suppresses cancer. In the absence of P53 protein, patients develop cancer. The lesson we learn 
is that if a single letter of this four-letter AT/GC base pairs is altered by virus or by chemicals 
or by gene or by radiation, first a single normal cell becomes abnormal or cancerous. Over 
many replications, the mutated cell becomes cancerous. Repeated exposure to chemicals such 
as smoking tobacco several times a day, you could alter a single letter of AT/GC base pairs. If 
a single cell becomes defected, it will multiply and accumulate and an entire organ becomes 
cancerous. When the defected organ cannot function, we become ill.
Unfortunately, cancer is not localized at one place for long (we could have cut out the 
defected organ and throw it away); it spreads or metastasizes as I described above. Once it is 
Prevention, Detection and Management of Oral Cancer40
metastasized, the other organs lose their function; with too many defected organs, a patient 
cannot survive for long. When we examine the internal structure of tumors of a dead patient, 
we find it mostly consists of abnormal cells that have been altered.
Let me tell you what you can do to protect yourselves and what we can do to help you? If 
you want to protect yourselves from oral or lung cancers, stop taking tobacco in any form 
and in any kind. The best way we can help you is to pursue as vigorously as we could do to 
find other sensitive genes and try to replace them with healthy genes by a method called gene 
therapy. Gene therapy could work if a single gene is mutated. Unfortunately, several genes 
are mutated in oral lung cancers. Gene therapy fails, but drug therapy works. From here my 
work begins. Professor Ross and I design drugs to shut off multiple defected genes.
As I said above, although the book of life is written in 3.2 billion AT/GC base pairs, about 2% of 
the AT/GC base pairs contain 24,000 genes (specific instructions to make proteins), the rest of 
DNA is called the junk DNA. As I said above, it is not garbage that we throw away; it contains 
important gene switches, promoters, enhancers, etc. We keep it because someday we might be 
able to find out what additional information it may provide about us. We carry all 24,000 genes 
in every cell of our body, but less than 6000 genes are probably bad genes (mutated) that are 
linked to a variety of genetic defects leading to 6000 different diseases. Each of us does not carry 
all 6000 bad genes, but we do carry a single copy of at least 4–5 bad genes in our genome. They 
remain dormant because only one parent carries a single copy of a mutated gene. We need both 
bad copies of bad genes, one from each parent to get sick. We have inherited these bad genes 
from our parents. Our parents inherited these genes from their parents. One ancestor can pass 
on the same bad genes to her children and children’s children. Therefore, it is a wise idea not to 
marry within the same family tree. The more intermarriages among the same family members, 
the more bad genes tend to concentrate among fewer and fewer children of that family.
3.1.3. Nicotine N-oxide is a carcinogen
I could take tobacco extract samples to the lab and analyze its ingredients. First, I soak the 
tobacco in ammonia and extract with chloroform. All nitrogen bases are extracted in chlo-
roform. I could wash the extract with water to remove all water-soluble impurities and dry 
the extract and distill off the chloroform. I place the residue in long glass column filled with 
silica gel. I pour a solvent mixture which carries the residue down the column. It is called 
the separation of different components by chromatography. I shine the UV light on the glass 
column as the solvent flows down. Hundreds of different bands appear in different colors, 
corresponding to hundreds of components present in the tobacco tar. The largest band is 
nicotine. To confirm, I take a little sample from the band and inject in the MS (mass spectrom-
eter: the largest peak corresponds to the molecular weight of the nicotine). I could make the 
radiolabeled nicotine by adding C-14 diazomethane in sodium hydroxide. The reaction adds 
a radiolabeled methyl group to nicotine molecule. I inject the radiolabeled methyl nicotine 
to half a dozen mice. I collect their urine samples separately. Analysis of the urine sample 
shows that some mice produce no change and others produce a new chemical called nicotine 
N-oxide. All those mice in which the gene that produces monoamine oxidase was activated 
developed cancer. If you inject nicotine N-oxide to another set of a dozen mice, they all come 
down with various cancers. All aromatic N-oxides are carcinogens.
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Now, you know why Sir Winston Churchill, who smoked cigar all his life, never developed 
cancer, but film actor Yul Brenner smoked cigarettes and died of lung cancer. If you were to 
analyze their urine samples, you will find that Mr. Brenner urine contains nicotine N-oxide. 
The gene monoamine oxidase is activated in Brenner to make nicotine N-oxide not in Sir 
Winston. While Sir Winston lived, Brenner died.
While I was busy designing drugs, such as AZQ, to shut off genes which cause brain cancers, 
my colleagues in the other labs at NCI (National Cancer Institute) have isolated hundreds of 
chemicals from the tobacco tar which contains dozens of carcinogenic chemicals. If you would 
apply the tobacco tar on the skin of mice, within a few weeks, tumor develops on the skin 
surface. The major culprit is nicotine which is considered as one of the most addictive chemi-
cals. Some studies showed that it is even more addictive than many known narcotics such as 
marijuana, opiates, and heroin. Oral cancer (OC) is caused by chemicals released by chewing 
tobacco. Most football players chew tobacco; they call it smokeless tobacco. Smoking burns 
tobacco generating even more aromatic amines which are known carcinogens. Nitrosoamines 
bind to DNA producing mutations.
After the completion of the Human Genome Project, we have identified specific mutations 
responsible for a specific disease. Now, we design drugs to attack that specific mutation to 
shut off that gene. The completion of the Human Genome Project has the greatest impact on 
Figure 1. NIH Scientific Achievement Award. Aziridines as single strand DNA binding agent.
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developing drugs on a rational basis and for treating various cancers including the oral cancer. 
The technologies developed during the completion of the Human Genome Project (the tool 
kits which contain hundreds of restrictions enzymes to cut DNA ligase to join DNA pieces; 
using these tool kits, we can cut, paste, and copy genes) could be used to treat and prevent 
oral cancer. The recently completed Thousand Genome Project will pinpoint with precision 
and accuracy the specific damage to DNA nucleotides responsible for causing various oral 
cancers. Once the mutated genes on a specific chromosome are identified, we can design drugs 
to shut off those genes like we designed AZQ (US Patent 4,146,622) to attack brain tumor (for 
structure, see Figure 1).
Once the mutation sites and chromosome numbers are identified, we can diagnose, prevent, 
and treat the oral cancer either by gene therapy if a single gene mutation is responsible for 
causing any of the above cancers or by drug therapy if multiple mutations are involved. 
As I stated above, French Anderson and his colleagues have successfully developed gene 
therapy for treating SCID (severe combined immunodeficiency) syndrome; we could use the 
same method to cut and paste and replace the bad gene with the good gene in a virus which 
is used to infect the WBC obtained from the same patient. After harvesting the infected 
WBC, the transgenic WBC was injected back in the same patient to treat SCID. It worked 
and patients fully recovered. Several thousand SCID children are living a normal life. Gene 
therapy works with a single gene mutation, but not if the multiple mutations are responsible 
for causing diseases.
4. Historical background for drug design
On the other hand, if cancer is caused by multiple mutations, we could use drug therapy 
by preventing malignant cell replication developed by Ross by cross-linking both strands 
of DNA. Using dyes specific to OC cells as carriers for nitrogen mustard, as done by Ross 
in making Melphalan, we could also develop new class of drugs to attack cancer cells in the 
other parts of the oral cavity. The bad news is that there have been 13 different forms of oral 
cancer identified. The good news is that for designing a drug, we have to find a dye which 
colors one of these tumors. There are hundreds of dyes available for testing. Once we suc-
ceed in finding a dye, we could design drugs by using our method by attaching aziridines 
to attack that specific oral cancer by shutting off mutated genes by binding to a single strand 
of DNA. What would happen if we succeed and when next-generation sequencers produce 
inexpensive and fast sequencing genomes is that we could identify all mutated genes on all 
13 oral cancers with precision and accuracy and design drugs to shut off those genes.
In the laboratory of the Sir Walter Ross at the Royal Cancer Hospital of London University, 
England, I was trained to design drugs to attack mutated DNA shutting off mutated genes. 
Professor Ross had spent all his life working on “Biological Alkylating Agents” and published 
a series of paper including a book [9–13]. Using the same rationale, I worked with Professor 
Ross for almost 10 years at London University developing anticancer drugs. Instead of cross-
linking DNA with nitrogen mustards, I used aziridines to bind to a single strand of DNA 
shutting off the genes.
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During 10-year period in the Professor Ross’ Lab, I made over 120 such drugs to attack a solid 
tumor called the Walker carcinoma 256 in rats. The most effective drug was called CB 1954 (2-4, 
dinitrophenyl aziridinyl benzamide) (see structure in Figure 1). It was 70 times more toxic to the 
tumor cell [14]. It is the most effective drug ever made against the solid experimental tumor for 
which I was honored with the Royal Cancer Hospital’s Institute Cancer Research postdoctoral 
award. Why mutated DNA must be attacked is because mutated DNAs code for wrong amino 
acids which produce wrong protein and cause abnormal growth leading to cancers. The reason 
why we work on mouse model is that if you would compare the genome of man, mouse, and mon-
key, they are all mammalians and their genomes are very similar. Once you succeed in attacking 
mouse tumor, it opens gate to attack human tumors. Now, you know how challenging it is to shut-
ting off a mutated gene and how easy it is to introduce mutations in the same gene by smoking.
The good news about smokers is that they could see their own genome on their computers 
and could also see the progress of mutations of their own genomes before and after smoking. 
Now, I do not have to tell my best friends not to smoke. All I have to do is to give the two CDs 
of their genomes and let them see for themselves. Let them see on their own computers and 
compare the two genomes. First, CD taken soon after their birth and second taken after they 
become smokers. Before I talk about the sequence-specific tumors of oral and lung cancers, let 
me share with you how our genome, the book of our life, looks like before you smoke.
The basis of OC is that people who are chewing tobacco or inhaling burning tobacco by smok-
ing (as in India) or chewing betel quid, betel nut, etc. (as in Taiwan) causing major mutations 
in their genomes producing a host of chemicals which damage the normal function of the 
cell causing them to become abnormal or cancerous. To understand the molecular basis of 
cancers, we have to sequence the normal as well as cancer cell genomes for comparison.
To refresh your memory, I repeat. Carcinoma is the most common type of cancer. It begins in 
the epithelial tissue of the skin, or in the tissue that lines the internal organs, such as mouth, 
oral cavity, reparatory tract, and lungs. There are 220 different types of tissues in the normal 
human being. We have sequenced (read letter by letter the entire script of nucleotides, their 
numbers, and their orders in which they are arranged). After genome sequencing, we can 
compare with the sequence of oropharynx carcinoma with normal cell from nonsmokers. I 
am happy to inform you that we just completed the Thousand Genome Project. Now, we can 
compare thousands of the same mutated sequence a time. We can locate the specific mutations 
with precision and accuracy. To locate specific mutations, in all oral cavity cancers, similar 
comparison can be studied in several types of salivary gland cancers including adenoid cys-
tic carcinoma, mucoepidermoid carcinoma, and polymorphous low-grade adenocarcinoma. 
Tonsils and base of the tongue tissues also develop lymphomas.
Once a mutation is identified in a specific oral cancer, my job begins trying to find a dye which 
colors these tumors. Once a dye is found, I could attach the toxic groups to shut off their genes. 
There are hundreds of dyes and there are hundreds of their combinations. With AT and GC, 
four nucleotides of DNA, I get 64 combinations; imagine how many combinations I get from 
hundreds of dyes. Fortunately, there are finite combinations. I could find it. Suppose I want to 
design drugs to treat cancers of the oral cavity. The cancer begins in the epithelial tissue of the 
skin, or in the tissue that lines the internal organs, such as mouth, oral cavity, reparatory tract, 
and finally reaching lungs. We have been designing drugs to attack toughest solid tumor like 
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Walker carcinoma 256 in rats or glioblastoma in humans. It would be much easier to attack 
carcinoma. And also suppose that I find a single dye which specifically colors a specific car-
cinoma cell. Now, my work begins to attach aziridines or carbamate or both as we succeeded 
in making AZQ for attacking brain tumor. Nowadays, I have to submit the research proposal 
to the Safety Committee (IRB: Institutional Review Board) for their approval. Since I will be 
using highly toxic nerve gases and nitrogen mustard, the proposal will be rejected.
5. Drug design for treating cancer
Firtz Heber, a German Army officer, worked on the development of chemicals as a weapon 
of war. He was responsible for making deadly nerve gases and nitrogen mustards. Before the 
WWI, he was honored with a Nobel Prize for capturing nitrogen directly from the atmosphere 
by burning the element magnesium in the air forming its nitride. Upon hydrolysis, nitride 
is converted to its nitrate which is used as a fertilizer. Using this method, we could make 
unlimited amount fertilizer. Nitrate is also used for making explosive. Soon after the WWI, 
Heber was charged with a crime against humanity for releasing hundreds of cylinders of 
chlorine gas on the Western front killing thousands of soldiers in the trenches. When allied 
forces reached his residence, his son shot himself and his wife committed suicide. Heber went 
in hiding in Switzerland. After the war, German government got his release as a part of the 
peace negotiations. Heber returned home to hero’s welcome. Although he promised never to 
work on the nerve gases again, secretly he continued to develop more lethal analogs of highly 
toxic nitrogen mustards. It was Heber who first made the notorious bis-dichloroethyl methyl 
amine. Because it smells like mustard seeds, it is called as nitrogen mustard. During the next 
20 years, before the beginning of the WWII, hundreds of more toxic analogs of nitrogen mus-
tard were developed. The bad news is that they are highly toxic and the good news is that 
they shut off genes.
6. Rationale for developing anticancer drugs
Nitrogen mustard was mercilessly used during the WWII by both German and Italian armies 
against allied forces. Most soldiers exposed to nitrogen mustard were frozen to death. Their 
blood analysis showed a sharp decline in white blood cell (WBC). Since patients with the 
cancer of the blood called leukemia showed a sharp increase of WBC, Professor Ross and his 
group wondered if minimum amount of nitrogen mustard could be used to control leukemia 
in cancer patients. It was a success. For the following 30 years, Ross developed hundreds of 
derivatives of nitrogen mustard to treat a variety of cancers. His most successful drugs are 
chlorambucil, melphalan, and merophan [2–6, 14].
Radiolabeled study showed that nitrogen mustard shut off genes by binding to DNA by cross-
linking. At London University, I work for Professor Ross for almost 10 years first as his gradu-
ate student, then his post-doctoral fellow, and then as his special assistant. I worked with 
the deadliest nerve agents such as nitrogen mustards, carbamates, and aziridines developed 
during Hitler’s time for evil purposes. We are converting evil into good. These agents easily 
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pass through various layers of our skin from ectoderm to mesoderm to endoderm. They easily 
enter the cell nucleus destroying the beta and gamma cell which develop immunity. Then they 
enter the nuclear membrane where they find the stem cells. Stem cells differ from say skin 
cells. In stem cells, all 24,000 genes are functioning and they have not yet differentiated, but 
skin cells are differentiated and they have shut off all other genes except the skin cell genes.
To the above toxic agents, I attach dyes to attack one of the carcinoma cells. The toxic group 
is activated by cell’s enzyme to produce a positive carbon ion called carbonium ion. It is 
extremely reactive; it binds to all four nucleotides (AT and GC) which form the DNA. But 
it preferentially binds to N-7 of guanine killing the stem cells. Professor Ross and I have 
 demonstrated the attack on N-7 of guanine using the radiolabeled study.
If I am accidentally exposed to any of the above toxic agents, I do not die of mustard poison-
ing; I would be frozen to death. What happens is the following: each cell carries hundreds 
of mitochondrial cells (mitochondria are foreign cells called prokaryotes without nuclear 
membrane captured by human cells during the evolutionary period, millions of years ago; 
they live in symbiotic relationship; to perform daily function, mitochondria provide energy to 
human cells and human cells provide free food and free housing to the mitochondria) which 
carry energy-rich phosphate bonds. They produce energy by breaking phosphate bonds in 
which a chemical called ATP (adenosine triphosphate) is broken down to ADP (adenosine 
diphosphate) which is further broken down to AMP (adenosine monophosphate). As normal 
cell grows, an enzyme attaches inorganic phosphate to the AMP regenerating ATP. If mito-
chondrial cells die, there is no energy available.
As I said above, NIH is the largest biomedical center in the world. It has unlimited facilities 
(chemicals, equipment, and personnel). Twenty-one thousand best and brightest scientists 
selected from Ivy League schools work in 26 institutes in more than 3000 labs. I had sent NIH 
over 120 drugs for NCI screening program [14–16]. During the 3-year period at NIH labs, I 
Figure 2. 2004 NIH Scientific Achievement Award presented to Dr. Hameed Khan by Dr. Elias Zerhouni, the Director of 
NIH during the NIH/APAO award ceremony held on December 3, 2004. Dr. Khan is the discoverer of AZQ (US Patent 
4,146,622), a novel experimental drug specifically designed to shut off a gene that causes brain cancer for which he 
receives a 17-year royalty for his invention (License Number L-0I9-0I/0). To this date, more than 300 research papers have 
been published on AZQ. The award ceremony was broadcast live worldwide by the Voice of America (VOA). Dr. Khan 
is the first Indian to receive one of the America’s highest awards in Medicine.
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made AZQ (US Patent 4,146,622) and 45 patentable analogs [17–19]. Years later, I was hon-
ored for my work on developing AZQ. Almost 20 years later, for translating my work from 
mouse to man and making AZQ (US Patent 4,146,622) for treating brain cancer, I was honored 
with the “2004 NIH Scientific Achievement Award,” one of the America’s highest awards in 
medicine (Figure 2). I was also honored by the Government of India with Vaidya Ratna (Gold 
Medal) (Figure 3).
In spite of all the risks, fear, and challenges, the zeal and the enthusiasm that I had to design 
drugs to attack brain cancer like AZQ is not there to treat oral or lung cancers. Do you know 
why because I know in my heart, the patient once cured will go back to smoking again. He 
cannot help it; it is an addiction (Figure 4) [20, 21].
Figure 3. His excellency, Dr. A.P.J. Abdul Kalam, the President of India greeting Dr. A. Hameed Khan, discoverer of 
anticancer AZQ, after receiving 2004, Vaidya Ratna, the Gold Medal, one of the India’s highest awards in medicine at the 
Rashtrapathi Bhavan (Presidential Palace), in Delhi, India, during a reception held on April 2, 2004.
Figure 4. Gold Medal for Dr. Khan. Dr. A. Hameed Khan, a scientist at the National Institutes of Health (NIH), USA, and 
an American Scientist of Indian origin, was awarded on April 2, 2004. Vaidya Ratna, the Gold Medal, one of the India’s 
highest awards in medicine for his discovery of AZQ (US Patent 4,146,622) which is now undergoing clinical trials for 
treating brain cancer.




Firtz Haber was a hero to some for getting a Nobel Prize for capturing nitrogen directly from 
atmosphere by burning magnesium metal in the air and hydrolyzing magnesium nitride 
to produce nitrate the fertilizer. To others, he was the greatest criminal because he released 
hundreds of cylinders of chlorine gas at the Western front killing thousands of soldiers in the 
trenches. It was Haber who made the nitrogen mustard and its deadly analogs which were 
used during WWII. Soldiers exposed to nitrogen mustard burns died of a sharp drop in the 
white blood cell (WBC) count. Since all cancers showed a sharp increase in WBC count, Ross 
decided to use modified derivatives of nitrogen mustard to control the cancer growth. Ross 
was successful. He attached amino acid phenylalanine as a carrier for the nitrogen mustard 
moiety to make melphalan for treating pharyngeal carcinoma. Over a 10-year period, I made 
dozens of analogs of nitrogen mustards for Ross. The deadliest among them was the phenyl-
enediamine mustard. We use these compounds to check the sensitivity of the tumors in the 
tumor bank. If tumors in the tumor bank become resistant, we have to replace them with fresh 
more sensitive tumors for testing other compounds.
Proteins in our body are made of 20 amino acids. When Ross made melphalan by using 1 
amino acid out of 20, most of my colleagues thought that they could use the following 19 amino 
acid to treat all 13 forms of oral cancers including lung cancer: alanine, arginine, aspartic acid, 
asparagine, cysteine, glycine, glutamic acid, glutamine, histidine, isoleucine, leucine, lysine, 
methionine, phenylalanine (Ross used this amino acid to make melphalan for treating pharyn-
geal carcinoma), proline, serine, threonine, tryptophan, tyrosine, and valine.
Aliphatic nitrogen mustards are deadlier than aromatic nitrogen mustards. They decided not 
to proceed because they do not want to risk their life to save the life of nicotine addicts. If you 
want to save smokes’ life by risking your own, you are welcome to it. I will show you how to 
make the nitrogen mustard by describing Haber’s crudest method. Haber reacted methylamine 
with ethylene oxide to make 2-bis dihydroxy ethylene methyl amine. It was chlorinated by 
heating with phosphorus pentachloride in the phosphoric acid. If you noticed a faint smell of 
mustard seed, Congratulations, you got nitrogen mustard; you are dead. No matter how much 
precaution you take, after the experiment, if you take an alcohol swab of walls, doors, and 
knobs and run mass spectra of alcohol extract, you find a line corresponding to nitrogen mus-
tard. If you are exposed to nitrogen mustard and cross the threshold level, your WBC drops 
sharply and the energy-providing mitochondria die and you are most likely to freeze to death.
Will anyone approve this study, probably no one. Your IRB will reject your proposal; your 
safety committee will reject it and who will provide the funds for such study. No one.
Tobacco companies are rich and can afford to invest money in curing cancers. Since most of 
their work is conducted behind closed doors, why not make nitrogen mustard analogs of all 
other 19 amino acids. Like melphalan, they might find some of these analogs of amino acids 
of nitrogen mustard to cure oral to lung cancers. They could make money not only by giving 
cancers by selling tobacco products but also by treating some cancers.
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8. Ethical issues
Some of my best friends smoke and most of them are not scientists. Do I tell them not to 
smoke and keep their friendship? Not a chance. So I tell them experimental facts as gently as 
possible. My readers are my best friends. All I want is to make them think. If they think, my 
job as a friend is done.
Scientists in our group are working on different kinds of cancers. As I stated above, there 
are more than 220 different types of tissues and they could all become cancerous if they are 
exposed to radiations or chemical environmental pollution. We are all working to cure those 
cancers. Unfortunately, there is no great enthusiasm for working on either oral cancer or lung 
cancer. Such diseases are considered self-inflicting wounds. The users of tobacco products 
are addicted and frequently developed these types of cancers. Many scientists believe that all 
of us have a free will. We have a right to live and we have a right to die. If you do not smoke 
or chew tobacco, you will not expose yourself to a host of carcinogens. Some of us believe 
that you are addicted to nicotine if we cure your oral cancer, you will go back and chew 
tobacco again. How can we protect you from yourself? If we protect you from yourself, we 
create a monster. On the other hand, if you are one of those unfortunate persons who inherit 
a mutated gene, or exposed to secondhand smoking or exposed to radiations or heavy metal 
particles, you deserve all our help and many of us have been designing drugs for treating oral 
and lung cancers for these innocent victims.
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